Research
Hormonal
Aerobic exercise training significantly improves insulin resistance (HOMA-IR) and fasting serum glucose levels in individuals with Type II Diabetes.
Regular aerobic exercise directly improves how your body uses insulin and lowers your fasting blood glucose levels. This is a key benefit of exercise for managing Type II Diabetes, alongside improving overall fitness and HbA1c.
StrongSupportsHIGH confidence
Homeostatic model assessment of insulin resistance (HOMA-IR) was also improved with exercise MD: -1.02, 95% CI -1.77, -0.28; p value = 0.007; as was fasting serum glucose MD: -12.53 mmol/l, 95% CI -18.94, -6.23; p value <0.0001
Why this rating
Meta-analysis with significant p-values for both outcomes.
Source
Clinical outcomes and glycaemic responses to different aerobic exercise training intensities in type II diabetes: a systematic review and meta-analysis
Aimee Grace et al. · Cardiovascular Diabetology · 2017
DOI 10.1186/s12933-017-0518-6
Meta-analysis · 27 studiesCited 178×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Aerobic exercise training significantly reduces HbA1c levels in individuals with type II diabetes, with the magnitude of reduction increasing as program duration extends beyond 12 weeks.Strong
- Vigorous intensity aerobic exercise produces superior improvements in cardiorespiratory fitness (peak VO2) compared to low or moderate intensity exercise in Type II Diabetes patients.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →